Study comparing margetuximab combinations to trastuzumab combinations in HER2-positive breast cancer

2022 KU Post San Antonio Review | Metastatic HER2 Positive Breast Cancer: Novel Treatment ApproachesПодробнее

Study of Immunotherapy Combinations for Patients with HER2-Positive Metastatic Breast CancerПодробнее

Dr. Pegram on Pertuzumab Combination for HER2-Positive Breast CancerПодробнее

Dr. Pegram on Margetuximab Plus Chemo in HER2+ Breast CancerПодробнее

SOPHIA Trial in R/R HER2+ mBCПодробнее

HER2CLIMB: tucatinib in combination w/ capecitabine & trastuzumabПодробнее

Margetuximab for the treatment of HER2-positive breast cancerПодробнее

Tucatinib Combination Improved Survival in HER2–Positive Breast CancerПодробнее

ONT-380 in Combination With Capecitabine and Trastuzumab in HER2-Positive Breast CancerПодробнее

Study of Atezolizumab with Pertuzumab and Trastuzumab in HER2- Positive Metastatic Breast CancerПодробнее

A presurgery combination therapy may improve outcomes for women with HER2 positive breast cancerПодробнее

ABP 980, a trastuzumab biosimilar in combination with pertuzumabПодробнее

Margenza (Margetuximab)- treatment of adult patients with metastatic HER2- positive breast cancerПодробнее

Immunotherapy Combination in HER2-Positive Breast CancerПодробнее

Adjuvant trastuzumab emtansine vs paclitaxel and trastuzumab for HER2-positive breast cancerПодробнее

DESTINY-Breast04: exploring T-DXd and IO combinations in HER2-low breast cancerПодробнее

Dr. Kalinsky on Ruxolitinib Plus Trastuzumab in HER2-Positive Breast CancerПодробнее

Treatment Updated for HER2 Positive Breast Cancer: Changing ParadigmsПодробнее

Dr. Blackwell Discusses Margetuximab for HER2+ Breast CancerПодробнее